CD5 is expressed in approximately 85% of T cell malignancies, such as T-cell lymphoblastic lymphoma (T-LBL) and peripheral T-cell lymphoma (PTCL). A recent study has demonstrated that anti-CD5 CAR-T cells effectively eliminated malignant T cells (31). This evidence concerns the gene CD5 and peripheral T-cell lymphoma, not otherwise specified.